atumelnant (CRN04894) / Crinetics - LARVOL DELTA

Once-Daily Oral Atumelnant (CRN04894) Induces Rapid, Substantial, and Sustained Reductions of Androstenedione and 17‑Hydroxyprogesterone in Adults With Classical Congenital Adrenal Hyperplasia: Interim Results From a 12-Week, Phase 2, Open-Label Study (ENDO 2025) - "Abstract is embargoed at this time."

Clinical • P2 data • Congenital Adrenal Hyperplasia • Endocrine Disorders

Reductions in Adrenal Volume in Patients With Congenital Adrenal Hyperplasia Receiving Once-Daily Oral Atumelnant (CRN04894): Interim Results From a 12-Week, Phase 2, Open-Label Study (ENDO 2025) - "Abstract is embargoed at this time."

Clinical • P2 data • Congenital Adrenal Hyperplasia • Endocrine Disorders

CRN04894-09: An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894 (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: Crinetics Pharmaceuticals Inc. | Initiation date: Nov 2024 ➔ Feb 2025

Trial initiation date • Congenital Adrenal Hyperplasia • Endocrine Disorders

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) - "Key Upcoming Milestones: Crinetics expects to begin enrollment of patients in two pivotal studies of atumelnant in CAH: Phase 3 in adults and Phase 2b/3 in pediatrics; Crinetics is also planning a study of atumelnant in Cushing’s disease. Enrollment of patients is expected to begin in late 2025 or early 2026."

New P2/3 trial • New P3 trial • New trial • Congenital Adrenal Hyperplasia • Cushing’s Disease

Advances in pharmacological treatment of Cushing's disease. (PubMed, Zhong Nan Da Xue Xue Bao Yi Xue Ban) - "Currently, three categories of medications are commonly used: 1) Drugs targeting somatostatin and/or dopamine receptors to inhibit pituitary adrenocorticotropic hormone (ACTH) synthesis (e.g., pasireotide, cabergoline); 2) drugs targeting adrenal cortex-related receptors to suppress steroid synthesis (e.g., ketoconazole, metyrapone, mitotane, and osilodrostat); 3) drugs acting on glucocorticoid receptors (e.g., mifepristone). Research on pharmacological treatments for Cushing's disease is ongoing, with new drugs such as seliciclib, CRN04894, fimepinostat, vorinostat, and SPI-62 currently in phase II clinical trial. The development of novel drugs holds promise for more precise and effective treatment for Cushing's disease patients."

Journal • Review • Cardiovascular • Cushing’s Disease • Endocrine Disorders

An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894 (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: Crinetics Pharmaceuticals Inc.

New P2 trial • Congenital Adrenal Hyperplasia • Endocrine Disorders

Atumelnant (crn04894) Induces Rapid And Sustained Reductions In Serum And Urine Cortisol In Patients With Acth-dependent Cushing Syndrome During A Phase 1b/2a, Single Center, 10-day, Inpatient, Open-label Study (ENDO 2024) - "Abstract is embargoed at this time."

Clinical • Late-breaking abstract • P1/2 data • Cushing’s Disease • Endocrine Disorders

Once Daily Oral Atumelnant (CRN04894) Induces Rapid And Profound Reductions Of Androstenedione And 17-hydroxyprogesterone In Participants With Classical Congenital Adrenal Hyperplasia: Initial Results From A 12-week, Phase 2, Open-label Study (ENDO 2024) - "Abstract is embargoed at this time."

Clinical • Late-breaking abstract • P2 data • Congenital Adrenal Hyperplasia • Endocrine Disorders

Discovery of CRN04894: A Novel Potent Selective MC2R Antagonist. (PubMed, ACS Med Chem Lett) - "Oral administration of 17h suppressed ACTH-stimulated corticosterone secretion in a dose-dependent manner at doses ≥3 mg/kg. With its satisfactory pharmaceutical properties, 17h was advanced to Phase 1 human clinical trials in healthy volunteers with the goal of moving into patient trials to evaluate CRN04894 for the treatment of ACTH-dependent diseases, including congenital adrenal hyperplasia (CAH) and Cushing's disease (CD)."

Journal • Congenital Adrenal Hyperplasia • Cushing’s Disease • Endocrine Disorders • MC4R

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: Crinetics Pharmaceuticals Inc. | Phase classification: P1b/2a ➔ P1/2

Phase classification • Cushing’s Disease • Endocrine Disorders

Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) - "Initial data from Phase 2 study of paltusotine in carcinoid syndrome expected December 2023. The Phase 2 open-label study of paltusotine in carcinoid syndrome associated with neuroendocrine tumors is completing enrollment....Based on successful Phase 1 studies demonstrating pharmacologic proof-of-concept, Crinetics is advancing clinical studies of CRN04894 in both Cushing’s disease and congenital adrenal hyperplasia. Data from the ongoing studies are expected in the second half of 2024."

Clinical data • P2 data • Carcinoid Syndrome • Congenital Adrenal Hyperplasia • Cushing’s Disease